Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04792684 · ClinicalTrials.gov registry record
Collection of Samples USOPTIVAL Study
A clinical trial of Colorectal Cancer (CRC) and Advanced Adenomas (AA), sponsored by Universal Diagnostics.
- Recruiting
- Registry status
- 1,300
- Enrollment target
- 16
- Study locations
NCT04792684 is a study of Colorectal Cancer (CRC) and Advanced Adenomas (AA) that is actively recruiting participants, run by Universal Diagnostics. The registered enrollment target is 1,300 participants, above the 334-participant average among 19 other Colorectal Cancer (CRC) trials with a reported enrollment target (289% higher). The trial reports 16 study locations across 10 states.
The verdict
NCT04792684, a study of Colorectal Cancer (CRC) and Advanced Adenomas (AA), is actively recruiting participants, sponsored by Universal Diagnostics.
- RECRUITING
- Registry status
- 1,300 participants
- Enrollment target
- 16
- Study locations
Study Summary
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Study Locations (16)
California
- Precision Recearch Institute - Chula Vista
- Precision Research Institute - San Diego
- Medical Associates Research Group - San Diego
- Clinical Research of California - Walnut Creek
Pennsylvania
- University of Pennsylvania - Philadelphia
- Fox Chase Cancer Center - Philadelphia
- Frontier Clinical Research - Uniontown
Florida
- Center for Gastrointestinal Disorders - Hollywood
- Lakeland Regional Cancer Center - Lakeland
Illinois
- Springfield Clinic - Springfield
Louisiana
- Ochsner Clinic - New Orleans
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Mid Hudson Medical Research - New Windsor
Tennessee
- Clinical Trials Network - Union City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,300 participants |
| Start Date | 2020-12-30 |
| Est. Completion | 2025-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04792684
The ClinicalTrials.gov registry entry for NCT04792684 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 334-participant average among 19 other Colorectal Cancer (CRC) trials with a reported enrollment target (289% higher). The listed sponsor is Universal Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer (CRC) appearing as the primary indexed condition, and to 1 intervention - of which Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel is the first listed.
NCT04792684 reports 16 study locations spanning 10 distinct geographic areas - top geographies include California, Pennsylvania, Florida.
Frequently Asked Questions
What is clinical trial NCT04792684 about?
NCT04792684 is a clinical study titled "Collection of Samples USOPTIVAL Study". A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
What is the current status of trial NCT04792684?
This trial is currently recruiting. The enrollment target is 1,300 participants. The study started on 2020-12-30. Estimated completion is 2025-12-30.
What conditions does trial NCT04792684 study?
This clinical trial studies the following conditions: Colorectal Cancer (CRC), Advanced Adenomas (AA).
What interventions are being tested in trial NCT04792684?
The interventions under investigation include: Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04792684?
This trial is sponsored by Universal Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04792684 being conducted?
This trial has 16 study locations across California, Florida, Illinois, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer (CRC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RECRUITING · Phase 1
-
Evaluation of Gixam's Performance in a FIT Negative Population
RECRUITING · Phase 2
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
RECRUITING · Phase 1
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.